Efficacy of chemotherapeutic agents under hypoxic conditions in pulmonary adenocarcinoma multidrug resistant cell line

Journal of Chemotherapy

Volumn 19, Issue 2, 2007, Pages 203-211

  Yu, Shicang ^a   Huang, Guijun ^a   Qian, Guisheng ^a   Li, Yuying ^a   Wu, Guoming ^a   Guo, Ruiling ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cytotoxic drugs; Hypoxia; Multidrug resistance; Normoxia; Pulmonary adenocarcinoma

Indexed keywords

ANTIINFECTIVE AGENT; CISPLATIN; DAUNORUBICIN; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; MITOMYCIN C; REACTIVE OXYGEN METABOLITE; VINCRISTINE;

ARTICLE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HYPOXIA; IC 50; LUNG ADENOCARCINOMA; MULTIDRUG RESISTANCE;

EID: 34247854842     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2007.19.2.203     Document Type: Article

References (46)

1. Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 2000; 35 (2): 71-103.
2. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1a in common human cancers and their metastases. Cancer Res 1999; 59 (22): 5830-5835.
3. Dales JP, Garcia S, Meunier-Carpentier S, et al. Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: Retrospective study in a series of 745 patients. Int J Cancer 2005; 116 (5): 734-739.
4. M Hockel, P Vaupel. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93 (4): 266-276.
5. Wykoff CC, Pugh CW, Harris AL, Maxwell PH, Ratcliffe PJ. The HIF pathway: Implications for patterns of gene expression in cancer. Novartis Found Symp 2001; 240: 212-225.
6. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002; 62 (12): 3387-3394.
7. Wartenberg M, Ling FC, Muschen M, et al. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by Hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J 2003; 17 (3): 503-505.
8. Wartenberg M, Gronczynska S, Bekhite MM, et al. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular prostate tumor spheroids by hyperthermia and reactive oxygen species. Int J Cancer 2005; 113 (2): 229-240.
9. Hug V, Johnston D, Finders M, Hortobagyi G. Use of growth-stimulatory hormones to improve the in vitro therapeutic index of doxorubicin for human breast tumors. Cancer Res 1986; 46 (1): 147.
10. Lee WP. The role of reduced growth rate in the development of drug resistance of HOB1 lymphoma cells to vincristine. Cancer Lett 1993; 73 (2-3): 105.
11. Valeriote F, van Putten L. Proliferation-dependent cytotoxicity of anticancer agents: A review. Cancer Res 1975; 35 (10): 2619.
12. Wilson WH, Teruya-Feldstein J, Fest T, et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 1997; 89 (2): 601-609.
13. Haq R, Zanke B. Inhibition of apoptotic signaling pathways in cancer cells as a mechanism of chemotherapy resistance, Cancer Metastasis Rev 1998; 17 (2): 233-239.
14. Bartussek C, Naumann U, Weller M. Accumulation of mutant p53 (V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status. Exp Cell Res 1999; 253 (2): 432-439.
15. Liu S, Bishop WR, Liu M. Differential effects of cell cycle regulatory protein p21 (WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy. Drug Resist Updat 2003; 6 (4): 183-195.
16. Rebbaa A, Chou PM, Mirkin BL. Factors Secreted by human neuroblastoma mediated doxorubicin resistance by activating STAT3 and inhibiting apoptosis. Mol Med 2001; 7 (6): 393-400.
17. Krtolica A, Ludlow JW. Hypoxia arrests ovarian carcinoma cell cycle progression, but invasion is unaffected. Cancer Res 1996; 56 (5): 1168-1173.
18. Webster L, Hodgkiss RJ, Wilson GD. Cell cycle distribution of hypoxia and progression of hypoxic tumour cells in vivo. Br J Cancer 1998; 77 (2): 227-234.
19. Krucher NA, Krtolica A, Lincoln J, Khan SA, Rodriguez-Rodriguez L, Ludlow JW. Mitogenic activity of steroidogenesis-inducing protein (SIP) during hypoxic stress of human ovarian carcinoma cells. Cancer Lett 1998; 133 (2): 205-214.
20. Zhenhong Hu, Qilin Peng, Qingquan Li. Effect of hypoxia on invasion and migration of lung carcinoma cells and its molecular basis. Chinese J Pathophysiol 2004; 20 (6): 973-975.
21. Hong Huang, Zhenxiang Zhang, Yongjian Xu, Jingfang Shao. HDAC1 expression and effect of TSA on proliferation and apoptosis of A549 cells. Chinese J Cancer 2003; 22 (9): 922-926.
22. Raghunand N, Gillies RJ. pH and drug resistance in tumors. Drug Resist Updat 2000; 3: 39-47.
23. Mahoney BP, Raghunand N, Baggett B, Gillies RJ. Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in Vitro. Biochem Pharmacol 2003; 66 (7): 1207-1218.
24. Gillies RJ, Deamer DW. Intracellular pH: Methods and applications. Curr Topics Bioenergetics 1978; 9: 63-87.
25. Roos A. Weak Acids, weak bases, and intracellular pH. Respiration Physiology 1978; 33 (1): 27-30.
26. Tannock IF, Rotin D. Acid pH in Tumors and its potential for therapeutic exploitation. Cancer Res 1989; 49 (16): 4373-4384.
27. Roepe PD. Analysis of the steady-state and initial rate of doxorubicin efflux from a series of multidrug-resistant cells expressing different levels of P-glycoprotein. Biochemistry 1992; 31 (50): 12555-12564.
28. Gerweck LE, Seetharaman K. Cellular pH gradient in tumor versus normal tissue: Potential for exploitation for the treatment of cancer. Cancer Res 1996; 56 (6): 1194-1198.
29. Doroshow JH. Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents. Biochem Biophys Res Commun 1986; 135 (1): 330-335.
30. Fulda S, Susin SA, Kroemer G, Debatin KM. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res 1998; 58 (19): 4453-4460.
31. Ravid A, Rocker D, Machlenkin A, et al. 1,25-Dihydrooxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res 1999; 59 (4): 862-867.
32. Friesen C, Fulda S, Debatin KM. Induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state in chemosensitive- and drug-resistant tumor cells. Cell Death Differ 1999; 6 (5): 471-480.
33. Sasaki M, Kobayashi D, Watanabe N. Augmented adriamycin sensitivity in cells transduced with an antisense tumor necrosis factor gene is mediated by caspase-3 downstream from reactive oxygen species. Jpn J Cancer Res 2001; 92 (9): 983-988.
34. Jie Chen, Chunxue Bai, Guishen Qian, Guijun Huang. Establishment of A549/CDDP multidrug resistant cell line. China oncology 2003; 13 (2): 186-187.
35. Koch S, Mayer F, Honecker F, Schittenhelm M, Bokemeyer C. Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in Vitro. Br J Cancer 2003; 89 (11): 2133-2139.
36. Greijer AE, de Jong MC, Scheffer GL, Shvarts A, vanDiest PJ, van-der-Wall E. Hypoxia-induced acidification causes mitoxantrone resistance not mediated by drug transporters in human breast cancer cells. Cell Oncol 2005; 27 (1): 43-49.
37. Krishnamurthy P, Ross DD, Nakanishi T, et al. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 2004; 279 (23): 24218-24225.
38. Shu Xia, Yu Shiying, Xianglin Yuan, Sanpeng Xu. Effects of hypoxia on expression of P-glycoprotein and mutltidrug resistance protein in human lung adenocarcinoma A549 cell line. Natl Med J China 2004; 84 (8): 663-666.
39. Raghunand N, Martinez-Zaguilan R, Wright SH, Gillies RJ. pH and drug resistance II: Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs. Biochem Pharmacol 1999; 57 (9): 1047-1058.
40. Skvortsova I, Skvortsov S, Haidenberger A, et al. Effects of paclitaxel and docetaxel on EGFR-expressing human carcinoma cells under normoxic versus hypoxic conditions in Vitro. J Chemother 2004; 16 (4): 372-380.
41. Fardel O, Jigorel E, Le Vee M, et al., Physiological, pharmacological and clinical features of the multidrug resistance protein 2. Biomed Pharmacother. 2005; 59 (3): 104-14.
42. DiDonato M, Narindrasorasak S, Forbes JR, Cox DW, Sarkar B. Expression, purification, and metal binding properties of the N-terminal domain from the Wilson disease putative copper-transporting ATPase (ATP7B). J Biol Chem 1997; 272 (52): 33279-82.
43. Izquierdo MA, Scheffer GL, Flens MJ, Schroeijers AB, van-der-Valk P, Scheper RJ. Major vault protein LRP-related multidrug resistance. Eur J Cancer 1996; 32A (6): 979-984.
44. Wachsberger PR, Landry J, Storck C, et al. Mammalian cells adapted to growth at pH 6.7 have elevated HSP27 levels and are resistant to cisplatin. Int J Hyperthermia 1997; 13 (3): 251-255.
45. Gabr A, Kuin A, Aalders M, El-Gawly H Smets LA. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH. Cancer Res 1997; 57 (21): 4811-6.
46. Bhattacharya A, Toth K, Mazurchuk R, et al. Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy. Clin Cancer Res 2004; 10 (23): 8005-8017.